Аннотация: В работе рассмотрен современный коммерческий способ производства самого востребованного в онкологии радиофармацевтического диагностического лекарственного средства 18F-Фтордезоксиглюкозы (2-фтор,18F-2-дезокси-D-глюкоза, 18F-ФДГ), представлены технологические стадии и операции синтеза, процедуры контроля качества, кратко описаны требования, предъявляемые к упаковке и маркировке данного радиофармацевтического препарата. Список литературы 1. Kam Leung. [18F]Fluoro-2-deoxy-2-D-glucose in Molecular Imaging and Contrast Agent Database (MICAD). National Center for Biotechnology Information, NLM, NIH, Bethesda, MD. 2005. 2. Min-Fu Yang, Diwakar Jain, Zuo-Xiang He. 18F-FDG Cardiac Studies for Identifying Ischemic Memory. Curr Cardiovasc Imaging Rep. 2012; Dec, 5:383-389. 3. Ghesani M., Depuey E. G., Rozanski A. Role of F-18 FDG positron emission tomography (PET) in the assessment of myocardial viability. Echocardiography. 2005 Feb; 22(2): 165-77. 4. Nose H., Otsuka H., Otomi Y et al. Evaluation of normal physiologic left ventricular myocardial 18F-FDG uptake at fasting state. European Congress of Radiology. 2012. Vienna, Austria. URL: http://posterng.netkey.at/esr/ viewing/index.php?module=viewing_poster&doi=10.1594 /ecr2012/C-1192 2012. 5. Dong Soo Lee, Sang Kun Lee, Myung Chul Lee. Functional Neuroimaging in Epilepsy: FDG PET and Ictal SPECT. Korean Med Sci. 2001;16: 689-96. 6. Teune L. K., Bartels A. L., Leenders K. L. FDG-PET Imaging in Neurodegenerative Brain Diseases // Functional Brain Mapping and the Endeavor to Understand the Working Brain edited by Francesco Signorelli and Domenico Chirchiglia, 2013. 7. Sanchez-Catasis C. A., Vallez, Garcha D., Le Riverend Morales E., Galvizu Sбnchez R. Traumatic Brain Injury: Nuclear Medicine Neuroimaging .PET and SPECT in Neurology. 2014; 923-946. 8. Masangkay N., Basu S., Moghbel M. et al. Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun. 2014 Oct; 35 (10): 1038-46. 9. Статистика злокачественных новообразований в России и странах СНГ в 10. Jones S. C., Alavi A., Christman D. et al. The radiation dosimetry of 2 [F-18]fluoro-2-deoxy-D-glucose in man. J Nucl Med. 1982; 23, 613-617. 11. Kuwabara H., Gjedde A. Measurements of glucose phosphorylation with FDG and PET are not reduced by dephosphorylation of FDG-6-phosphate. J Nucl Med. 1991 Apr; 32(4): 692-8. 12. Data are from International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals. St. Louis, MO. Elsevier; 2000:49. ICRP publication 80. 13. Ido T., Wan C. N., Fowler J. S. Fluorination with F2: convenient synthesis of 2-deoxy-2-fluoro-d-glucose. J Org Chem. 1977; 42: 2341-2. 14. Hamacher K., Coenen H. H., Stacklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]- fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986; 27: 235-8. 15. Toorongian S. A., Mulholland G. K., Jewett D. M. et al. Routine production of 2-deoxy-2-[18F]fluoro-D- glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Int J Rad Appl Instrum B. 1990; 17 (3): 273-9. 16 Нормы радиационной безопасности (НРБ- 99/2009). СП 2.6.1.2523-09. 17. Основные санитарные правила обеспечения радиационной безопасности (ОСПОРБ-99/2010). СП 2.6.12612-10. 18. СанПиН 2.6.1.3288-15 «Гигиенические требования по обеспечению радиационной безопасности при подготовке и проведении позитронной эмиссионной томографии». 19. N.A. Gomzina, D.A. Vasil’ev, R.N. Krasikova. Optimization of Automated Synthesis of 2-[18F]Fluoro- 2-deoxy-D-glucose Involving Base Hydrolysis. Radiochemistry. 2002; 44 (4): 403-409. 20. Gopal B. Saha. Basics of PET Imaging: Physics, Chemistry and Regulations. - 3th ed. - New York: Springer International Publishing, 2016; 165.